Navigation Links
Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
Date:6/2/2008


CINCINNATI, June 2 /PRNewswire-FirstCall/ --

CALL DATE: Tuesday, June 3, 2008

TIME: 9:30 a.m. Eastern Time

HOST: Dr. Candace Kendle, Chairman and CEO

Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast on Tuesday, June 3 at 9:30 a.m. Eastern Time to discuss the acquisition of DecisionLine Clinical Research Corporation that was announced on May 30 and to provide an update on second quarter progress. A question and answer session will follow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

Webcast Instructions

To access the live webcast, go to http://www.kendle.com or http://www.videonewswire.com/event.asp?id=48934 . Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on July 3, 2008. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx .

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on July 3 by dialing (706) 645-9291 and entering conference ID number 50042856.

About Kendle

Kendle (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning 90 countries, along with industry- leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202, United States or from the company's Web site at http://www.kendle.com


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
2. Kendle Appoints Patricia Williams Vice President, Commercial Operations
3. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
4. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
5. Kendle Leaders Adopt 10b5-1 Trading Plans
6. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
7. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
8. Kendle to Present at the Wachovia 2008 Healthcare Conference
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
11. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):